Edition:
United States

Tetraphase Pharmaceuticals Inc (TTPH.OQ)

TTPH.OQ on NASDAQ Stock Exchange Global Select Market

5.96USD
2:48pm EST
Change (% chg)

$0.21 (+3.65%)
Prev Close
$5.75
Open
$5.75
Day's High
$6.00
Day's Low
$5.63
Volume
192,634
Avg. Vol
217,103
52-wk High
$9.69
52-wk Low
$3.59

Chart for

About

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral... (more)

Overall

Beta: 2.54
Market Cap(Mil.): $295.63
Shares Outstanding(Mil.): 51.41
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.50 16.04
EPS (TTM): -- -- --
ROI: -- 15.11 35.70
ROE: -- 16.59 15.40

BRIEF-Tetraphase Pharmaceuticals Q3 loss per share $0.63

* Tetraphase pharmaceuticals reports third quarter 2017 financial results and highlights recent clinical and corporate achievements

Nov 02 2017

BRIEF-Tetraphase Pharmaceuticals signs commercial supply agreement with Finorga

* Tetraphase Pharmaceuticals Inc says ‍on October 16 co and finorga sas entered into a commercial supply agreement​ - sec filing

Oct 20 2017

BRIEF-TETRAPHASE PHARMACEUTICALS APPOINTS KAM UNNINAYAR AS CFO

* TETRAPHASE PHARMACEUTICALS APPOINTS KAM UNNINAYAR AS CHIEF FINANCIAL OFFICER

Oct 16 2017

BRIEF-Tetraphase Pharmaceuticals presents clinical data from oral eravacycline development program at IDWEEK 2017​

* Tetraphase Pharmaceuticals - ‍phase 2 trial in patients with complicated urinary tract infections expected to begin in h1 2018​

Oct 04 2017

BRIEF-Tetraphase Pharmaceuticals completes enrollment of ignite3 phase 3 clinical trial of eravacycline

* Tetraphase Pharmaceuticals completes enrollment of ignite3 phase 3 clinical trial of eravacycline in complicated urinary tract infections

Sep 11 2017

BRIEF-Tetraphase announces validation of IV eravacycline MAA by European Medicines Agency

* Tetraphase Pharmaceuticals announces submission and validation of IV eravacycline marketing authorization application by European Medicines Agency

Aug 17 2017

BRIEF-Tetraphase announces pricing of public offering of common stock

* Tetraphase announces pricing of public offering of common stock

Jul 27 2017

BRIEF-Tetraphase announces proposed public offering of common stock

* Tetraphase announces proposed public offering of common stock

Jul 26 2017

BRIEF-Tetraphase announces positive top-line results from Phase 3 IGNITE4 Clinical Trial

* Tetraphase Pharmaceuticals announces positive top-line results from phase 3 IGNITE4 clinical trial in complicated intra-abdominal infections

Jul 25 2017

Tetraphase's antibiotic succeeds late-stage study, shares soar

Tetraphase Pharmaceuticals Inc said its lead experimental antibiotic for serious bacterial infections met the main goal in a late-stage study, sending its shares surging nearly 23 percent in after-market trading on Tuesday.

Jul 25 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $142.08 +0.43
Pfizer Inc. (PFE.N) $36.46 -0.18
Merck & Co., Inc. (MRK.N) $56.01 -0.90
AstraZeneca plc (AZN.L) 4,881.00 -3.50

Earnings vs. Estimates